The NYSE-listed firm announced the first commercial implant of `Allure Quadra’, a cardiac resynchronisation therapy pacemaker (CRT-P), in the country.

The first-to-market quadripolar pacemaker system offers more pacing options for patients with heart failure (HF), a company release said here.

Quadripolar leads allow for increased implant efficiencies, which clinical data indicates can result in fewer surgical revisions. Broad clinical evidence on the advantages of the quadripolar technology has been documented in more than 100 publications worldwide, it said.

Explaining how this new technology works, Anil Saxena of Fortis Escorts Hospital, said: “Historically, pacing systems that treat heart failure included a lead with only one electrode in the heart. Later, these were replaced by leads with two electrodes.

“Nearly 40 per cent of patients do not effectively benefit from traditional pacing due to potential complications all of which require repeat surgeries.”

The new technology has four electrodes and 10 programmable pacing configurations, allowing electro-physiologists to manage their patients with greater flexibility and improved patient outcomes, Saxena said.

The worldwide prevalence of heart failure has been rising over the last few decades. More than 26 million people globally suffer from HF, with a prevalence rate in India estimated to range from 1.3 to 4.6 million people.